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ABSTRACT - Hysteresis loops are phenomena that sometimes are encountered in the analysis of 
pharmacokinetic and pharmacodynamic relationships spanning from pre-clinical to clinical studies. When 
hysteresis occurs it provides insight into the complexity of drug action and disposition that can be encountered. 
Hysteresis loops suggest that the relationship between drug concentration and the effect being measured is not a 
simple direct relationship, but may have an inherent time delay and disequilibrium, which may be the result of 
metabolites, the consequence of changes in pharmacodynamics or the use of a non-specific assay or may involve 
an indirect relationship. Counter-clockwise hysteresis has been generally defined as the process in which effect 
can increase with time for a given drug concentration, while in the case of clockwise hysteresis the measured 
effect decreases with time for a given drug concentration. Hysteresis loops can occur as a consequence of a 
number of different pharmacokinetic and pharmacodynamic mechanisms including tolerance, distributional 
delay, feedback regulation, input and output rate changes, agonistic or antagonistic active metabolites, uptake 
into active site, slow receptor kinetics, delayed or modified activity, time-dependent protein binding and the use 
of racemic drugs among other factors. In this review, each of these various causes of hysteresis loops are 
discussed, with incorporation of relevant examples of drugs demonstrating these relationships for illustrative 
purposes. Furthermore, the effect that pharmaceutical formulation has on the occurrence and potential change in 
direction of the hysteresis loop, and the major pharmacokinetic / pharmacodynamic modeling approaches 
utilized to collapse and model hysteresis are detailed. 
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A central tenet of clinical pharmacotherapeutics is 
that there often exists a relationship between drug 
concentration and pharmacological and 
toxicological effects for drugs. The most common 
pharmacokinetic-pharmacodynamic (PK-PD) 
models assume that plasma concentration is in 
equilibrium and proportional with the effect site 
(biophase) concentration. In its simplest form a 
plasma drug concentration versus effect graph 
demonstrates a direct linear relationship between 
the two variables where effect is directly 
proportional to drug concentrations at the active site 
and this relationship is independent of time [1] 
(Figure 1a).Where equation 1 is: 
CSE   (1) 
E is the effect, C is the drug concentration and S is 
the slope parameter. This linear function model 
does not predict a maximum pharmacological effect 
(Emax). The relationship between drug concentration 
and pharmacological effect more often follows a 
sigmoidal Emax model (Hill equation) (Figure 1b). 
This simple mathematical relationship is based on 
receptor theory that defines the drug concentration 
effect relationship with two parameters Emax and 
EC50 (the concentration producing 50% of the 
maximum effect). It allows for differences in the 
shape of this relationship, where n is the number of 
molecules combining with each receptor molecule 
that affects the shape of the curve. The relationship 
between drug concentration at the receptor and the 
response is defined using equation 2.  
_________________________________________ 
Corresponding Author: Dr. Neal M. Davies, Faculty of 
Pharmacy, University of Manitoba, Winnipeg, Manitoba, 
Canada. Email: neal_davies@umanitoba.ca 


















E is the observed effect, Emax is the theoretical 
maximal effect that can be attained, C is the 
concentration, EC50 is the C value that produces an 
effect equivalent to 50% of the theoretical maximal 
effect and n is a slope factor parameter that 
determines the steepness of the curve. The time 
courses of drug effect and concentrations may not 
be completely superimposable. Time-dependent 
concentration-effect relationships exist with a time 
lag present between measurable effect and 
measurable concentration. In these cases, when 
pharmacodynamics and drug concentration data are 
connected in time series at a later point compared 
with a previous time point there is a discordance in 
the plasma concentration versus effect relationship 
with respect to time. Hence, the magnitude of 
pharmacological effect either increases or decreases 
at any given plasma drug concentration. The term 
“hysteresis” has been utilized to describe this time 
lag. The term “hysteresis” is derived from the Greek 
husterēsis or husteros meaning ‘shortcoming, to 
come late or to come behind’. Hysteresis is the 
dependence of a system on both its current and past 
environments. Figure 1c and d present the graphical 
evidence of a temporal relationship of dependence 
between the pharmacological effect and the drug 
plasma concentration. As the data modeling field in 
pharmaceutical science examining the concentration 
versus effect relationships and simulations has 
grown, there has been some debate regarding the 
terminology used to describe these phenomena 
when encountered. It has been suggested that 
instead of using the term clockwise hysteresis, the 
moniker “proteresis” should be employed. 
“Proteresis” is a term also derived from the Greek 
language with proteros meaning ‘former, before or 
to mark an earlier event’. Similarly, instead of 
stating that a “counter-clockwise” or “anti-
clockwise” hysteresis is present it was proposed to 
simply state the vernacular of ‘hysteresis’ to avoid 
redundancy [2]. However, the term ‘proteresis’ has 
not become the conventional lexicon and most 
studies in the literature still utilize the appellatives 
‘clockwise’ or ‘counter-clockwise’ hysteresis. For 
consistency and clarity in this review clockwise 
hysteresis will be used instead of proteresis, and 
counter-clockwise hysteresis instead of simply 
hysteresis or anti-clockwise hysteresis. 
In the counter-clockwise scenario (Figure 1 c) 
there is often non-instantaneous distribution of a 
drug to the effect site (biophase), as the drug 
appearance is delayed into the pharmacodynamic 
(PD) effect site at a slower rate than that in which it 
appears in plasma, this temporal delay in delivery 
results in a mismatch between declining 
concentrations and the response [3, 4]. When the 
biophase is not in the central compartment, it 
exhibits a counter-clockwise hysteresis loop when 
followed over time (Figure 1c). In this instance, 
there is a small effect at a given drug concentration; 
however, after some time has passed the same drug 
concentration gives rise to a greater measured effect 
than expected. Thus, the same drug concentration 
produces two different magnitudes of 
pharmacological effects depending on the temporal 
sequence in which the effect is measured. Counter-
clockwise hysteresis has been generally defined as 
the process in which effect increases with time for a 
given drug concentration [5]. These phenomena can 
be caused by uptake into an active site, cascade 
activity, active metabolites or sensitization (Table 
1) [5]. 
In the opposite scenario a hysteresis loop may 
also occur where a clockwise hysteresis loop is 
evident, for example if tolerance is developed to a 
drug such as an opioid (Figure 1d). Here it can be 
seen that the same plasma concentration has a 
greater effect early on in temporal sequence and 
that after some time the effect diminishes at the 
same plasma concentration. In the case of clockwise 
hysteresis the measured effect decreases with time. 
These phenomena can be mechanistically induced 
by active antagonistic metabolites, tolerance, 
learning effects, or feed-back regulation etc. (Table 
1) [5]. 
An analysis of the pharmaceutical literature 
using PubMed, EMBASE and Google Scholar 
searches indicates that there are many plausible 
mechanistic proposed reasons for explaining the 
findings of hysteresis loops in drug concentration 
versus effect plots (Tables 1-3). Situations that may 
lead to a clockwise hysteresis are the development 
of tolerance to a drug, antagonistic metabolites that 
are formed as the drug is metabolized, down-
regulation of receptors and feedback regulation [6]. 
Some potential causes for counter-clockwise-
hysteresis include distribution delay between the 
plasma and effect site, response delay, sensitization 





of receptors, the formation and subsequent 
accumulation of active metabolites through drug 
metabolism as well as up regulation of receptors 
after ongoing exposure [6, 7]. Once this type of 
hysteresis loop relationship has been discovered 
further mathematical modeling, such as the effect 
compartmental modeling, or one of its many 
modifications such as indirect modeling, can be 
applied to the data to take into account lag times, 
formation of active metabolites or multiple receptor 
sites in order to mechanistically define and simplify 
the concentration-effect relationship [1]. 
As hysteresis loops become readily evident 
during attempts to correlate the pharmacokinetic 
(PK) measurement [concentration (C)] of a drug 
with its measured PD measurement [effect (E)], an 
accurate determination of the PD measurement  is 
critical.[8] In general, most of the clinical 
pharmacology study designs include in vivo PK and 
in vivo PD endpoint measurements; however, in the 
case of antibiotics or immunosuppressants it is 
common to have in vivo non-steady state dosing of 
drug, and the sampled matrix is used to determine 
in vitro PD effect, which can make the 
interpretation of hysteresis more straightforward. 
However, in early stages of drug 
discovery/development analytical assays are 
sometimes incapable of differentiating parent drug 
from its metabolite(s) and therefore would not be 
able to account for the presence/degree of in vivo 
pharmacological active metabolite(s) [8]. From the 
pharmacological and mechanistic point of view, 
counter-clockwise and clockwise hysteresis loops 
are a phenomenon that occurs under specific 
conditions, and the amount, activity and potency of 
parent and metabolite ratio is a key concept in the 
development and direction of a determined 
hysteresis. 
Counter-clockwise hysteresis loops in PK-PD 
relationships could be explained and defined [319] 
as a consequence of a number of factors illustrated 
below in Figure 2. 
 
Counter-clockwise Hysteresis 
1. Disequilibrium caused by a temporal 
displacement can occur because of rate limiting 
steps: 
Step A: Instantaneous equilibrium between C 
and effect site concentrations (Ce) is not attained, 
which results in a temporal displacement (between 
C and Ce), where C(t) in plasma and Ce in the effect 
site are not identical and C(t) > Ce.[8] 
Step B: The rate of change of Ce is much 
greater than the rates of pharmacological receptor 
activation/deactivation (R*). For instance the 
number of activated receptors (R*) is not reflective 
of Ce at time (t), resulting in a temporal 
displacement (between Ce > and R*).[8] 
Step C: The overall rate of conversion of signal 
transduction induced by R* to measured E is much 
less than the rate of change of R* so that E(t) is not 
equal to R*(t), resulting in temporal displacement 
between R* >and E. The concentration (C) of drug 
binding with a receptor (R) forms a transient (CR) 
drug-receptor complex and this altered complex is 
affected by the receptor association and dissociation 
on and off the receptor. Kd is the receptor 
dissociation rate constant and is equal to the ratio of 
Koff/Kon.  
2. Transformation of a drug or prodrug into 
a metabolite(s) with agonist actions (MPCA / 
MPPCA or MPNCA) are formed from the 
parent drug (D or E) and are included in the 
contribution of the combined measurement of 
E.  
Step D: Common Receptor-Common 
Transduction Mechanism MPCA or MPPCA is 
a competitive agonist or competitive partial 
agonist with lower intrinsic activity, for which 
it occupies the same receptor (R*) as the parent 
drug concentration [EmaxMPCA or Emax MPPCa 
is less than Emax(C)]  
Step E: Separate Receptor-Common 
Transduction Mechanism. Metabolite with non-
competitive agonist actions (MNCA) occupies 
a different receptor but the same effect is 
achieved through a similar mechanism. 
Step J: Separate Receptor Separate 
Transduction Mechanism MNCA is a non-
competitive agonist, for which a different 
pharmacological receptor (R2) is occupied but 
the same E achieved through a different 
mechanism.  
3. Step K: Changes in PD over time. PD has 
a distinct temporal component. For instance, up 
regulation of receptor response (R*) (Step K) 
(sensitization) when the EC50 might reduce 
over time. 
4. Indirect physiological mechanism of drug 
action with changes in PD over time. A 
biosensor process leads to a positive 





modulation in production Kin or a negative 
change in degradation Kout of the biosignal may 
occur and be transduced (Step L) into an E. 
5. The measurement of C(t) is not specific and 
analysis should seek to measure the active 
component. 
A. Total (unbound and bound) drug analyzed is 
being measured over time rather than unbound 
concentration of drug being measured over time and 
time-dependent protein binding due to protein 
binding changes over time are occurring such that 
unbound pharmacologically active concentration 
reduces with time.[9] 
B. Total achiral (all enantiomers) drug 
concentration is being measured over time rather 
than enantiospecific concentration of a racemic 
drug through the use of non-stereospecific assays 
[10]. Stereospecific pharmacokinetics and 
pharmacodynamics are occurring leading to 1. 
Stereospecific disequilibirum 2. Stereospecific 
metabolism and/or 3. Stereospecific changes in PD 
occurring. 
a) Common Receptor-Common Transduction 
Mechanism Stereospecific Competitive 
Agonist/Partial Agonism. 
b) Separate Receptors-Common Transduction 
Mechanisms. One enantiomer with non-competitive 
agonist actions occupies a different receptor but the 
same effect is achieved through a similar 
mechanism. 
c) Separate Receptor Separate Transduction 
Mechanism. One enantiomer is a non-competitive 
agonist, for which a different pharmacological 
receptor (R2) is occupied but the same E achieved 
through a different mechanism.  
C. Total (parent drug + metabolites) 
concentration together are being measured by a 
non-specific  analytical assay (i.e. 
radioimmunoassay, radioactive assay, or high 
performance liquid chromatographic assay, etc.), 
which is non-specific for the parent drug such that 
an assumed E vs. C plot is in actuality an E vs. 
C+MPCA or E vs. C+MPPCA plot. 
5). A specific analytical assay has been 
developed to measure C, however, an unknown or 
unidentified agonist metabolite is adding to the E. 
 
Clockwise hysteresis 
Clockwise hysteresis loops in PK-PD relationships 
could be explained and defined as a consequence of 
a number of factors illustrated below in Figure 3. 
1. Disequilibrium caused by a temporal 
displacement that occurs because of a major rate 
limiting step: Step A: Disequilibrium occurs when 
Ce temporally precedes C(t). For instance, the rate of 
equilibration between arterial plasma concentrations 
(compartment delivering drug to effect site) and 
venous plasma concentrations (sampling 
compartment for drug concentration analysis) is 
significantly less between arterial concentrations 
and Ce such that C(t) is not equal to Ce(t), resulting in 
temporal displacement (between C(t) and Ce.)  
2. Metabolite(s) with antagonistic actions 
(MpCAn) are formed. Step D: Common Receptor-
Common Mechanism. MpCAn is a competitive 
antagonist with no intrinsic activity, for which the 
same receptor (R*) is occupied as the administered 
drug concentration but it lacks pharmacological 
activity [Emax(MANTCA)~0 <<<< Emax(C)] so that 
receptor blockade occurs.[8] 
Step G: Common Receptor-Common 
Transduction Mechanism. MPPA is a partial 
competitive agonist with low intrinsic activity, for 
which it occupies the same receptor (R*) as the 
parent drug concentration [Emax(MPOa) is less than 
Emax(C)]  
Step J: Separate Receptor-Separate Mechanism. 
MpCA is a non-competitive antagonist (reverse 
agonist), for which it interacts with a different 
receptor (R1) than the drug concentration 
administered and has opposing effects over the 
measured E(t). 
Step N. Changes in PD over time. PD has a 
measurable temporal component. For instance, with 
tolerance down regulation of receptors leads to EC50 
to increase and/or the Emax would decrease 
overtime. 
3. Indirect mechanism of drug action with 
changes in PD over time. A biosensor process leads 
to a negative modulation of production Kin or a 
positive increase in degradation in Kout of the 
biosignal may occur and be transduced (Step O) 
into E.  
4. Counter regulatory feedback regulation (Step 
P). 
5. The measurement of C(t) is not-specific.  
A. Total (unbound and bound) drug measured is 
being measured over time rather than unbound free 
concentration of drug being measured over time and 
time-dependent protein binding  such as the protein 
binding changes over time are occurring such that 
unbound pharmacologically active concentration 
decreases with time [9].  






Figure 1. (a) Representation of a linear relationship between plasma concentration of a drug and measured pharmacological 
effect (b) Representation of a Sigmoidal Emax model relationship between plasma concentration of a drug and measured 
pharmacological effect (c) Representation of counter-clockwise hysteresis between plasma concentration and measured 




Figure 2. Factors Influencing Counter-clockwise Hysteresis  
Cp(t) = Plasma parent drug concentration, Ce(t) = “Effect site” concentration, R*(t) = Receptor site, E(t) = Effect, MPCA(t) = 
Metabolite(s) in plasma which are competitive agonists, MeCA(t) = Metabolite(s) in “Effect site” which are competitive 
agonists,  MPNCA(t) = Metabolite(s) in plasma which are competitive agonists /(MPPCA) partial agonists which have non-
competitive agonist action acting on a different receptor BUT same Effect, MeNCA(t) = Metabolite(s) in “Effect site” 
which are competitive agonists which have non-competitive agonist action acting on a different receptor BUT same Effect, 
R2 = Alternate receptor site (with same Effect). 
 
B. Total achiral (all enantiomers) drug 
concentration is being measured over time rather 
than enantiospecific concentration of a racemic 
drug through the use of non-stereospecific assays 
[10]. 
Stereospecific pharmacokinetics and 
pharmacodynamics are occurring leading to 1. 
Stereospecific Disequilibrium, 2. Stereospecific 
Metabolism and/or 3. Stereospecific Changes in PD 
occurring. A. Common Receptor-Common 
Mechanism Competitive Antagonism, where one 
enantiomer is active and the other has affinity but 
no activity. 
B. Total (parent drug + metabolites) concentration 
together are being measured by a non-specific  
analytical assay is being utilized (i.e. 
radioimmunoassay, radioactive assay, or high 
performance liquid chromatographic assay, etc.) 
that is non-specific for the parent drug such that an 
assumed E vs. C plot is in actuality an E vs. 
C+MpCAN or E vs. C+MpCA plot. 
A specific analytical assay has been developed to 
measure parent compound concentration, however, 
an unknown or unidentified antagonist metabolite is 
adding to the E. 







Figure 3. Factors Influencing Clockwise Hysteresis  
Cp(t) = Plasma parent drug concentration, Ce(t) = “Effect site” concentration,R*(t) = Receptor site, E(t) = Effect, MpCAn(t) 
= Metabolite(s) in plasma which are competitive antagonists, MeCAn(t) = Metabolite(s) in “Effect site” which are 
competitive antagonists, MpCA(t) = Metabolite(s) in plasma which are competitive antagonists which have competitive 
agonist action acting on a different receptor BUT same Effect, MeCA(t) = Metabolite(s) in “Effect site” which are 
competitive antagonists which have competitive agonist action acting on a different receptor BUT same Effect, R1 = 
Alternate receptor site (with same but opposite Effect). 
 
 
Table 1. Mechanistic Explanations for Hysteresis 
Counter-clockwise Hysteresis Clockwise Hysteresis 
Sensitization (up regulation of receptors) Tolerance (down regulation “desensitation” of receptors) 
Input rate  Input rate 
Distribution delay  into the site of Effect Disequilibrium between arterial and venous concentrations 
 Active agonist metabolite Active antagonistic metabolite 
Indirect effect( positive input or negative output) Indirect effect ( negative input or positive output) 
Slow receptor kinetics Feedback regulation 
Time dependent protein binding  Time dependent protein binding 
Racemic drugs and  non-stereospecific assays  Racemic drugs and non-stereospecific assays 
 
 
The following overview of hysteresis loops 
aims to provide a comprehensive rather than 
exhaustive appraisal of the available pharmaceutical 
and biomedical literature in which hysteresis in 
either direction has been observed or studied.  The 
goal of this article is to provide the reader with a 
more comprehensive understanding of the 
mechanistic reasons underlying why these 
phenomena can occur, provide examples of which 
drugs and group of drugs have been reported to 
exhibit these characteristics  (Table 2 and 3), the 
effect that pharmaceutical formulation may have on 
the occurrence and change in direction of a 
hysteresis loop, and the main pharmacokinetic-
pharmacodynamic modeling approaches utilized to 
further understand hysteresis relationships. 
 
COUNTER-CLOCKWISE HYSTERESIS 
A counter-clockwise hysteresis loop may signify an 
increasing pharmacological effect compared with 
earlier temporal pharmacological effects obtained 
with the same plasma concentration of drug. There 
are a variety of examples in the literature that 
suggest this type of pharmacokinetic / 
pharmacodynamic relationship as demonstrated in 
Table 2 [11-79, 298-312, 318, and 327-329]. A 
counter-clockwise hysteresis may mechanistically 
   





manifest due to a variety of underlying mechanisms 
as discussed below. 
 
Distribution Delay into Site of Effect 
Counter-clockwise hysteresis loops can occur 
because of a distribution delay between the 
systemic drug concentration and the time to reach 
the effect site. This is the most commonly 
encountered underlying mechanism responsible for 
the finding of a counter-clockwise hysteresis loop. 
Effect-concentration is time-dependent and an 
indirect link is made between the two variables. 
For example, a delay for a drug to be 
transported from the systemic circulation to its site 
of action to elicit a response has been reported for 
∆-9-tetrahydrocannabinol (THC) after intravenous, 
oral or smoking administration, and after various 
intravenous doses [107]. It was observed that 
counter-clockwise hysteresis was evident after 
intravenous and smoking administration because 
THC takes a finite time in order to equilibrate with 
one of its sites of action (brain). However, it was 
also observed that after oral administration no 
hysteresis loop was evident because more time was 
allowed for penetration into the brain [107]. In the 
case of intravenous and smoking administration, the 
time necessary to reach equilibrium was 
approximately 15 minutes (Figure 4a). Furthermore, 
it can be observed that the counter-clockwise 
hysteresis loop was evident after all the intravenous 
doses (Figure 4b), indicating that this phenomenon 
is both dose and route-independent [107]. It can be 
observed that the location and the protective 
barriers surrounding the active site, in this case the 
brain, plays a critical role in the occurrence of 
hysteresis. As the brain possesses multiple 
protective barriers such as the blood-brain barrier 
(BBB) it could be expected that a delay in reaching 
the site of action would occur. This type of 
hysteresis was also observed for morphine after 
subcutaneous administration (14 µmol/kg) to rats  
with renal failure in which counter-clockwise 
hysteresis was developed between anti-nociceptive 
activity and morphine plasma concentrations, which 
correlated with an equilibrium delay as the 
consequence of the ability of morphine to cross the 
BBB [58]. 
The organic nitrate isosorbide dinitrate (ISDN) 
exhibited counter-clockwise hysteresis after 
intravenous infusion (0.133 mg/min for 15 min) or 
sublingual (5 mg) administration (Figure 5) [44]. It 
was observed that the changes in standing systolic 
pressure were greater during the declining phase 
than in the ascending phase after IV and sublingual 
administration [44], this correlated with previous 




                      
 
Figure 4. Counter-clockwise hysteresis of ∆-9-tetrahydrocannabinol (THC) plasma concentrations versus self-reported 
subjective “High” effect (a) different routes of administration and (b) different dosages. Reprinted by permission from 
Macmillan Publishers Ltd: Clinical pharmacology and therapeutics, [107], copyright 1984. 
a  b






Figure 5. Relationship between plasma ISDN concentration and response after intravenous (●) and sublingual (○) dosing. 
Reprinted by permission from Macmillan Publishers Ltd: Clinical pharmacology and therapeutics, [44], copyright 1983. 
 
 
The proposed mechanism for this hysteresis was a 
delay in distribution to the active site in tissue, a 
delay in saturation at the receptor level because it is 
a non-instantaneous event, or contribution of 
vasoactive metabolites [109, 110] which are less 
active than parent drug [44]. However, the main 
factor responsible appears to be the delay in 
equilibrium between the plasma and the site of 
action [44].  
 
Slow Receptor Kinetics 
Drug receptor theory states that as drug 
concentration increases the occupancy of the 
receptor will increase rapidly at first but then it will 
progressively decrease as the receptors become 
occupied, and that the drug concentrations 
necessary to achieve maximal effect (Emax) can be 
many fold higher than that necessary to produce a 
50% response. [5]. However, not all drug receptor 
interactions can be described by an Emax model 
since there are limitations in the type of binding, 
regulation, type of receptors, and the use of 
surrogate sample-feasible biological matrices (i.e. 
blood) instead of the actual receptor binding site 
[5]. However, besides the limited access of drugs to 
the site of action the presence of slow receptor 
kinetics are recognized as one of the main causes of 
counter-clockwise hysteresis [111]. It has been 
reported that in the case of anti-psychotic drugs 
they need to traverse not only the BBB but also the 
transporters that reside in this barrier [12]. The rate 
at which drugs bind to the receptor (kon) and the rate 
at which it dissociates from a receptor (koff) 
determine the kinetics of a drug such as in the case 
of anti-psychotic drugs and their relationship with 
the dopamine D2 receptor [12]. For these types of 
drugs the kon values show low variability for various 
drugs, but the koff can vary within a 1000-fold range 
[112]. This switching movement has been evaluated 
by positron emission tomography (PET) studies in 
dopamine receptor occupancy after single oral 
administration of aripiprazole (2, 5, 10 or 30 mg) to 
healthy subjects, which reported that a high receptor 
occupancy was present after administration (lower 
arm of hysteresis), but low receptor occupancy was 
observed at later time points post-drug 
administration (upper arm of hysteresis) [12]. 
In the case of telmisartan, an angiotensin 
receptor antagonist, counter-clockwise hysteresis 
was observed between plasma concentration and 
angiotensin II response after oral administration 
(20, 40 or 80 mg) following an angiotensin II 
challenge [74]. It was determined that the hysteresis 
could be explained because of the tight binding and 
subsequent slow dissociation of telmisartan from 
the receptor (AT1) on the vascular smooth muscle 
cells [74], which was based on the 3H-telmisartan 
binding to rat lung AT1 receptors and slow 
dissociation (t1/2 = 5.9 h) from the binding sites 
[113]. Furthermore, the slow dissociation from the 
AT1 receptor can also contribute to the antagonism 
of telmisartan [74, 114]. Similarly, candesartan 
cilexetil and losartan after oral dosing exhibited 
counter-clockwise hysteresis after angiotensin II 
challenge in healthy subjects, and it was reported 
that candesartan exhibited a slower off-rate from the 
AT1 receptor than losartan [22]. However, the 
extent of insurmountable antagonistic activity [115-
117] or differences in distributional phenomena 
could also occur. The slow onset of the inhibitory 





effect on blood pressure for candesartan  [23,118-
119]  could result in a longer than expected PD 
effect based on the plasma concentrations [22]. On 
the contrary, in the case of irbesartan the 
pharmacological effects in the renin-angiotensin 
system (RAS) are related to the blockade of AT1 
receptors by increasing the plasma angiotensin II 
and plasma renin activity for which an actual 
clockwise hysteresis was reported [92]. It was 
reported that the duration of the antagonism of AT1 
receptor for irbesartan would be longer than 
predicted using plasma concentrations [92] as 
demonstrated after single 150 mg PO for which the 
antagonism lasted for 2 days, which was much 
longer than valsartan and losartan [120]. 
 
Delayed or Modified Activity 
The pharmacological response of a drug is not only 
bound by the rate of binding to a specific receptor, 
but can also be related to a progressive series of 
stochastic events that could cause a modification or 
delay in pharmacological activity. [63]. For both 
regular and neutral protamine Hagedorn (NPH) 
insulin after a single subcutaneous injection of 10 U 
or 25 U, the time to reach maximum infusion rate of 
glucose infusion (Rmax), namely TRmax, occurs at a 
later time than tmax indicating a delay between 
maximum serum concentrations and the maximum 
PD effect. This delay was more obvious for regular 
insulin, and when the serum concentrations were 
correlated with glucose infusion rate (GIR) values, 
a counter-clockwise hysteresis loop was observed 
for both types of insulin. As the difference in delay 
between regular and NHP insulin is appreciable, the 
hysteresis loop was greater for regular insulin than 
NPH insulin [63]. 
In the case of molsidomine [a prodrug for the 
formation of nitric oxide (NO)] it first requires 
biotransformation (rapid hydrolysis) to its active 
metabolite SIN-1, which downstream will release 
NO [56]. It is because of this metabolic delay in the 
formation of NO from SIN-1 that counter-clockwise 
hysteresis has been reported in the change of 
diastolic diameter after a single oral dose (4 mg) of 
molsidomine to coronary artery disease (CAD) 
patients [121]. These findings correlated with a 
separate study in which finger pulse curve as a PD 
effect exhibited counter-clockwise hysteresis after 




Active Agonist Metabolite 
As the existence of first pass metabolism occurs 
predominantly in the liver, the route of 
administration may play a critical role in the 
appearance of a hysteresis loop. Hysteresis is 
possible because a drug can be converted to an 
active metabolite that has a Cmax and a combined 
peak activity at a later time point compared to the 
parent drug [5]. For instance, midazolam exhibited 
a slower reaction time when administered orally 
compared to intravenous administration, and when 
the concentrations were combined (both oral and 
intravenous routes) a counter-clockwise hysteresis 
loop was evident. However, when the active 
metabolite α-hydroxy midazolam was analyzed, 
their combined concentrations gave similar reaction 
times regardless of the route of administration 
[123]. 
Itraconazole (ITZ) is a chiral oral active triazole 
anti-fungal agent that has non-linear PK in rats and 
humans and dose-dependent first pass metabolism 
[124-127], and it is also metabolized by CYP3A to 
the major chiral metabolite hydroxyitraconazole 
(OH-ITZ) that has similar anti-fungal activity 
compared to ITZ [125, 128]. Counter-clockwise 
hysteresis was observed between the ITZ and OH-
ITZ concentrations entering the liver (expressed as 
an average of portal venous and aortic 
concentrations, assuming that the liver receives 
25% of total blood flow via the hepatic artery and 
75% via the portal vein) after duodenal infusion of 
ITZ (5 or 40 mg/kg) to chronically catheterized rats 
[46]. Once the change in hepatic availability (FH) 
versus ITZ concentrations were plotted over time, a 
counter-clockwise hysteresis loop was observed 
indicating an equilibration delay between ITZ and 
effect (FH) or another factor that would control FH 
such as the production of an active metabolite. The 
importance of metabolism was evident because of 
the lack of hysteresis and only a direct hyperbolic 
relationship between FH and OH-ITZ. This lack of 
hysteresis indicates that this metabolite or some 
other factor with a similar time course would be the 
key regulator of CYP3A inhibition and the hepatic 
availability (FH) of ITZ. Similar relationships were 
obtained at the 40 mg/kg dose [46]. However, 
although analytical assays were capable of 
measuring the parent compound and its metabolite, 
no stereospecific analysis was undertaken to 
delineate the importance of chirality of this racemic 
drug and the influence of stereoselective 
metabolism, which should be considered in the 





interpretation of the mechanism underlying the 
hysteresis loop.  
The cholinesterase inhibitor eptastigmine was 
administered to healthy volunteers as a single oral 
dose (10, 20 or 30 mg), and counter-clockwise 
hysteresis was observed between plasma 
eptastigmine concentrations and both red blood cell 
acetyl-cholinesterase inhibition and plasma butyryl-
cholinesterase inhibition [32]. It was evident that 
eptastigmine is more effective and provides a longer 
duration in inhibition of cholinesterase in RBC 
(acetyl-cholinesterase) than in plasma (butyryl-
cholinesterase), which is similar to previous reports 
in young [129,130] and elderly subjects [131]. 
However, these previous  findings do not correlate 
with in vitro studies in which it has been reported 
that eptastigmine is more active on butyryl-
cholinesterase compared to acetyl-cholinesterase 
[132], which could be attributed to the formation of 
active metabolites such as 3'- and 5'-carboxylic acid 
derivatives and 3'-carboxylic acid-1-demethyl 
derivative [133]. Thus, the therapeutic drug 
monitoring should not be performed using the 
unchanged eptastigmine concentrations [32]. 
Furthermore, the observed counter-clockwise 
hysteresis in RBCs indicates that eptastigmine does 
not develop acute tolerance, which could be 
explained by the formation of active metabolites but 
also because eptastigmine slowly dissociates from 
acetyl-cholinesterase in RBCs [134]. The observed 
invertible character of the hysteresis loop in plasma 
butyryl-cholinesterase inhibition s suggests that 
eptastigmine reaches immediate equilibrium with 
the enzyme [32]. 
Furthermore, as presented by Gupta et al. [8] 
the potency of parent compound and the agonistic 
metabolite (MA) was estimated using generated 
plasma concentration-time and plasma 
concentration-effect curves. The degree of counter-
clockwise hysteresis increases as the agonistic 
metabolite accumulates [as elimination rate of the 
metabolite (kmo) decreases and is not formation rate 
limited]. Furthermore, the degree of hysteresis is 
also reflective of the potency of the parent 
compound and agonist metabolite MA since as the 
ratio of potency parent compound/agonist 
metabolite decreases in magnitude (potency of 
agonist metabolite increases), the degree of 
hysteresis will increase.  
Indirect Physiological Response 
Often drugs act via an indirect mechanism of action 
and the pharmacologic effect takes considerable 
time to become evident as concentrations of drug 
are decreasing. Response is governed by the 
stimulation or inhibition of factors which can 
modulate the response [320]. There are two indirect 
situations following drug administration where the 
response measured when related to drug 
concentrations will produce a counter-clockwise 
hysteresis. Counter-clockwise hysteresis occurs 
when input is stimulated (i.e. stimulating the release 
of an endogenous physiological factor) or the output 
is inhibited (inhibiting or degrading the release of 
an endogenous physiological factor). For example 
stimulation of insulin or prolactin leads to a 
counter-clockwise hysteresis and the inhibition of 
anticholinesterase or diuresis leads to a counter-
clockwise hysteresis [321-330] Terbutaline is a 
bronchodilator that increases cyclic AMP this in 
turn leads to bronchial smooth muscle dilation. 
Pyridostigmine and other agents inhibit 
cholinesterase preserving acetylcholine leading to 
an increase in muscular activity leading to a gain in 
muscular response. An indirect response can result 
in counter-clockwise hysteresis [321-323]. 
 
CLOCKWISE HYSTERESIS  
A clockwise hysteresis loop may signify a 
decreasing pharmacological effect compared with 
earlier temporal pharmacological effects obtained 
with the same drug concentration. There are a 
variety of examples in the literature that suggest this 
type of pharmacokinetic/ pharmacodynamic 
relationship as reported in Table 3 [80-102, 313-
317, and 330]. A clockwise hysteresis may 
mechanistically manifest due to a variety of 
underlying mechanisms as discussed below. 
 
Venous vs Arterial Blood Concentrations. 
Drug concentration is often measured in venous 
blood sampling sites and the site of effect 
equilibrates with arterial concentrations at different 
rates. When the effect site (i.e. the brain or heart, 
etc.) concentration at the receptor site (leading to 
drug effect) equilibrates faster with arterial 
concentration than forearm venous blood 
concentration, clockwise hysteresis may occur.  





           
 
Figure 6. (a) Opioid effect plotted against arterial remifentanil concentration from a representative subject (subject 12). 
Note the counter-clockwise direction of the hysteresis loop. (b) Opioid effect plotted against venous remifentanil 
concentration from a representative subject (subject 12). Note the clockwise direction of the hysteresis loop. Reprinted by 
permission from Macmillan Publishers Ltd: Clinical pharmacology and therapeutics, [69], copyright 1999. 
 
 
In the case of the opioid remifentanil after IV 
infusion (3 µg/kg/min for 10 min), it was observed 
that as opioid concentration increases the spectral 
edge decreases in the form of counter-clockwise 
hysteresis as a result of an equilibrium  delay 
between arterial remifentanil concentration and the 
site of action (brain) (Figure 6a) [69] . However, a 
significant difference in arteriovenous 
concentrations in healthy subjects was reported and 
the direction of the hysteresis loop was reversed in 
venous drug concentrations (Figure 6b) and it was 
determined that the venous concentration lag behind 
the drug effect (clockwise hysteresis) [69]. It was 
suggested that the arterial drug concentration and 
effect site reach equilibration faster than the 
equilibration between arterial and venous 
concentration [69,103-106]. 
Tolerance (Down Regulation of Receptors) 
Tolerance is a time-dependent loss of intrinsic 
activity that can occur within the time course of a 
single dose, and is called acute tolerance or 
tachyphylaxis. In the case of pharmacodynamic 
tolerance intrinsic responsivity of the receptor 
diminishes over time. Many drugs present 
clockwise hysteresis due to tolerance because they 
present a reduced pharmacological effect at the 
same concentration than earlier leading to an 
increased effect [140-145]. After oral 
administration of the benzodiazepine diazepam 
(0.28 mg/kg) clockwise hysteresis was observed 
between tracking or digit-symbol substitution 
impairment and unbound diazepam concentrations 
relative to receptor occupancy [85]. Acute tolerance 
to the psychomotor effects of other benzodiazepines 
like alprazolam [146,147], midazolam [148], and 
triazolam [149] has been reported. However, it 
needs to be acknowledged that the actual 
mechanism of tolerance development to 
benzodiazepines is poorly understood [81]. There is 
no consensus delineating the actual mechanism but 
there are reports that consider that a decrease in 
binding potential and/or decrease in receptor 
functionality could explain the appearance of 
tolerance [150]. However, other mechanisms such 
as desensitization associated with receptor 
phosphorylation, uncoupling, and protein 
internalization or degradation have been proposed 
[151]. 
In the case of temazepam (30 mg oral dose), 
clockwise hysteresis was observed between plasma 
concentration and sedation score with or without the 
co-administration of aluminum hydroxide gel (30 
mL) in end-stage renal patients (Figure 7) [101]. 
The hysteresis loops were very similar with or 
without the co-administration of aluminum 
hydroxide gel, but the main difference was the 
presence of the lag time of 1 h when temazepam 
was administered alone, but it was concluded that 
aluminum hydroxide gel had no effect on the 
absorption of temazepam [101]. The clockwise 
hysteresis was attributed to tolerance [152], which 
could be a consequence because of a discrepancy 
between its effective t1/2 and receptor binding 
affinity [153]; however, psychological adaptation 
[154] and functional disturbance [155] can also play 
a role since sedation has some subjectivity in 
a  b 





scoring, as a patient can force themselves to stay 
awake after an entire morning  of sleep or the 
opposite may occur [101]. 
Interestingly, when temazepam is administered 
as a racemate a clockwise hysteresis is evident in its 
sedation. It is likely that stereospecific 
pharmacokinetics and pharmacodynamics 
contribute to this relationship [9-10]. Use of a non-
stereospecific assay for a chiral drug could lead to 
an apparent clockwise hysteresis loop where this 
relationship might not be apparent if the 
stereospecific concentrations were measured. 
In the case of morphine after intragastric 
administration as a single dose (15 mg/kg) to rats, it 
was observed that clockwise hysteresis was evident 
between unconjugated and conjugated morphine 
concentrations and anti-thermal pain effect. It was 
proposed that the fast and short-lasting anti-thermal 
pain effect of unconjugated and conjugated 
morphine was due to tolerance [59]. Morphine 
administered as an IV bolus to rats caused less 
tolerance than IV infusions at two different rates, 
with tolerance stronger for the higher infusion rate 
[156]. Similarly when morphine was administered 
SC (14 µmol/kg) to rats tolerance (clockwise 
hysteresis) developed between antinociceptive 
activity and morphine brain concentrations in renal 
failure-induced rats, which has been suggested to 
most likely involve a post-opioid receptor 
transduction mechanism [58, 157]. 
In the case of diltiazem after a single oral dose 
(120 mg) to healthy subjects, clockwise hysteresis 
was observed in 4 out of 6 subjects (Figure 8) [86]. 
Significant effects on arteriovascular (AV) 
conduction were observed as expressed by the 
prolongation of PR interval, and because of the 
inverse relationship between PR interval and heart 
rate [158] diltiazem would decrease the heart rate in 
order to increase the PR interval [86]. Furthermore, 
acute tolerance has been reported for diltiazem after 
a single oral dose (180 mg) of sustained-release 
formulations to healthy subjects based on the 
observed clockwise hysteresis for PQ and PR 
interval prolongation [87]. However, previous 
reports indicated counter-clockwise hysteresis after 
a single IV administration of diltiazem [159-162], 
which could occur because a delay before 
equilibrium is reached between systemic and site of 
action concentrations, or the contribution of active 
metabolites [163]. But also because tolerance [164], 
arteriovenous differences during sampling [69, 165, 
166], or the presence of inhibitory metabolites with 
increasing metabolite-to-parent concentration ratio 
[164]. The arteriovenous equilibrium differences 
would result in time-dependence over short time 
intervals, but hysteresis occurred over an extended 
interval of many hours [86]. The metabolites N-
desmethyldiltiazem and desacetyldiltiazem [167-
169] are produced and have been reported to have 
equal or lower hemodynamic effects than parent 
drug  [170, 171]; however, it is unknown how 
active the unbound metabolites compete/react with 
the receptor active sites in contrast with diltiazem 
[86]. The proposed tolerance of diltiazem is not 
caused by compensating physiological mechanisms 
because a decrease in blood pressure would 
indirectly increase the heart rate; however, this does 
not appear to be evident [86].  
 
                
Figure 7. Relationship between mean plasma temazepam concentrations and the NRSS after TM (●) and TM + AHG (○). 
Reprinted by permission from Macmillan Publishers Ltd: Clinical pharmacology and therapeutics, [101], copyright 1985. 






Figure 8. Plots of change in PR interval versus concentration of diltiazem for each of the six subjects over 24 hours. The 
direction of the arrows indicates the chronologic order of the concentrations. Reprinted by permission from Macmillan 




Mammalian physiology has multiple feedback 
mechanisms to control various pathophysiological 
processes such as biochemical, nerve and enzymatic 
functions [5]. In the case of clockwise hysteresis 
these negative feedback mechanisms decrease the 
activity for the same concentration. For instance, 
when almitrine bismesylate (a respiratory stimulant)  
 
was infused (0.5 mg/kg) over 30 minutes to phase II 
chronic obstructive lung disease (COLD) patients, it 
was observed that almitrine concentrations 
increased to a plateau around 500 ng/mL at 30 
minutes but rapidly decreased after the infusion was 
over. Furthermore, oxygen levels (PaO2) reached a 
maximum around 15 minutes and rapidly declined 
exhibiting a clockwise hysteresis loop [172]. It has 





also been reported that in the case of almitrine, the 
production of a feedback mechanism would be 
present at higher concentrations than 500 ng/mL 
[173]. Furthermore, the formation of almitrine 
inhibitory metabolites has also been proposed as a 
mechanism, but these have been isolated and 
synthesized and reported to have poor uptake by the 
carotid body and have little activity in rats [174]. 
However, studies in cats have reported that 
almitrine stimulates the carotid body under the 
feedback mechanism of the automatic sympathetic 
ganglioglomerular nerve (GGN) and on a lesser 
intensity by the contralateral carotid nerve (CCN) 
[175]. 
 
Active Antagonistic Metabolite 
The occurrence of antagonistic metabolites is rare in 
the pharmacokinetic-pharmacodynamic literature. 
Typically metabolite concentrations are lower than 
parent drug in humans, and generally metabolites 
are more polar and less active than parent and may 
go unnoticed. However, if an antagonistic 
metabolite is present and with sufficient potency, 
the parent drug would appear to be less effective 
and could have a shorter activity [5]. This has been 
reported for oxyphenylbutazone affecting the 
elimination of phenylbutazone [176], 5-hydroxy-
pentobarbital and pentobarbital [177], and 
hydroxydiphenylhydantoin and hydantoin [178]. 
Clearly, the greater the potency of the antagonistic 
metabolite relative to the parent compound, and the 
slower the elimination rate constant relative to the 
parent drug, the larger the hysteresis loop [8]. 
 
Indirect Physiological Response 
Often drugs act in an indirect mechanism of action 
and the pharmacologic effect takes considerable 
time to become evident and response is governed by 
the stimulation or inhibition of factors that modulate 
the response [320]. There are two situations 
following drug administration where the response 
measured when related to drug concentrations will 
produce a clockwise hysteresis. Clockwise 
hysteresis occurs when input is inhibited or the 
output is stimulated. For example, acid secretion is 
inhibited by H2-receptor antagonists, and the 
formation of angiotensin II is inhibited by 
angiotensin converting enzyme inhibitors and 
certain anticoagulants such as warfarin that inhibit 
prothrombin complex activity, methylprednisone 
and other corticoids that inhibit cortisol. Similarly, 
diuretics such as furosemide may stimulate 
secretion of electrolytes into urine, and warfarin 
inhibits coagulation through prothrombin complex 
activity. In these situations we would readily expect 
the appearance of clockwise hysteresis if an effect 
versus concentration relationship is plotted [321-
323]. 
 
INPUT RATE: PHARMACEUTICAL 
FORMULATION EFFECTS AND THE 
DIRECTION OF HYSTERESIS LOOPS 
As various formulation efforts are designed to 
provide a desired therapeutic profile, variations in 
pharmacokinetics and pharmacodynamics are 
common. Thus, by altering the formulation in which 
a drug is prepared and thereby altering its input rate 
may also affect the direction of the hysteresis loop 
at various steps in the process (Figures 2 and 3). For 
instance, the loop diuretic bumetanide (1 mg) was 
administered orally to healthy subjects as tablets 
and as retarded capsules (containing sustained 
release granules) [20]. In the case of the tablet 
formulation a counter-clockwise hysteresis was 
present and it was determined that this was caused 
due to the time lag between plasma concentration 
and diuretic effect because bumetanide acts directly 
in the renal tubule or because of variations in 
absorption rate from the GI tract [20]. However, in 
the case of the bumetanide retarded capsules a 
clockwise hysteresis was evident in the relationship 
between urinary excretion rate and urine flow rate. 
In this case the urine flow rate maximum was 
achieved before the plasma Cmax or maximum of 
urinary excretion in the case of bumetanide [20]. 
Similar results were obtained with furosemide 
(another loop diuretic) for which minimal counter-
clockwise hysteresis was observed for plain tablets 
(Furix®) while controlled release formulations 
(Furix Retard® and Lasix Retard®) exhibited clear 
clockwise hysteresis when the diuretic effect versus 
furosemide excretion rate were correlated [38]. The 
occurrence of the counter-clockwise hysteresis 
indicated that after the administration of the plain 
tablet there was a minimal delay of the effect 
related to furosemide excretion rate. However, in 
the case of the clockwise hysteresis of the two 
controlled release formulations, tolerance and 
upregulation of the biosignal of the Na-Cl-K 
transporter protein may be the main mechanism of 
action responsible for the effect [38]. These results 
were parallel to the ones observed in a similar study 
where a regular tablet and a retarded furosemide 
capsules were administered to healthy subjects [39]. 





Therefore, the higher diuretic effect (related to the 
amount of excreted furosemide) could have been 
the result of the slower output of drug from the 
controlled release formulations compared to the 
plain tablet, indicating that the diuretic response is 
independent of intrinsic activity and maximum 
response [135]. 
Another relevant example includes 
lisdexamphetamine mesylate (prodrug that gets 
metabolized to D-amphetamine and L-lysine) and 
immediate-release (IR) D-amphetamine when it was 
administered intraperitoneally (IP) to rats at 
equivalent doses (1.5 mg/kg D-amphetamine base) 
[28]. Counter-clockwise hysteresis between D-
amphetamine (from lisdexamfetamine and IR D-
amphetamine) plasma concentrations and striatal 
dopamine efflux was evident [28]. The counter-
clockwise hysteresis was evident because the 
magnitude of the increase in extracellular dopamine 
was greater when the concentrations of D-
amphetamine were decreasing instead of increasing. 
When the D-amphetamine plasma concentrations 
were related with the locomotor activity, it was 
observed that lisdexamfetamine (1.5 or 5.0 mg/kg 
IP) presented counter-clockwise hysteresis, whereas 
there was no hysteresis for IR D-amphetamine, 
demonstrating the important effect of formulation in 
the PK-PD relationship. Hysteresis was also 
analyzed between the striatal extraneuronal 
dopamine concentration and locomotor activity 
[28]. In this case counter-clockwise hysteresis was 
evident for lisdexamphetamine; however, in the 
case of IR D-amphetamine clockwise hysteresis 
was observed because there was a greater locomotor 
response during the ascending portion of the 
dopamine concentration profile [28]. 
The observed differences in pharmacokinetics 
and hysteresis between lisdexamphetamine and IR 
D-amphetamine could be explained because the 
prodrug lisdexamphetamine is hydrolyzed by red 
blood cells and by a rate-limited enzymatic reaction 
to D-amphetamine [136]. This would cause a more 
sustained gradual release of D-amphetamine 
compared to the IR formulation causing a more 
prolonged and sustained efficacy [137-139]. The 
counter-clockwise hysteresis observed was linked 
with the requirement of D-amphetamine to cross the 
blood-brain barrier in order to enter the striatal 
nerve terminals before releasing dopamine to 
produce locomotor activity (functional outcome) 
[28]. Therefore, lisdexamphetamine would be a 
lesser stimulant than an equivalent dose of IR D-
amphetamine. However, lisdexamphetamine offers 
a later, more gradual and more sustained increase of 
striatal dopamine compared to a rapid achieving but 
rapidly declining effect for IR D-amphetamine [28].  
The calcium sensitizer levosimendan when 
administered as a single dose via different routes: 
IV infusion (2 mg for 5 min), slow-release tablet 
(SR, 2 mg), conventional tablet (CT, 2 mg) or 
conventional capsule (CC, 2 mg) to healthy humans 
exhibited counter-clockwise hysteresis in all the 
formulations for the electromechanical systole 
corrected for heart rate (QS2i) (Figure 9) [49]. It 
was observed that the SR formulation resulted in 
lower concentrations and generally weaker effects 
compared to the other formulations. The observed 
hysteresis was proposed to occur because of an 
equilibration delay that reflects the time that the 
drug is required to distribute from the plasma to its 
site of action (heart) and the difference between 
formulations may be due to the physiological 
barriers and physicochemical properties of the 
actual formulations that would render different 
absorption and distribution profiles [49]. 
Furthermore, counter-clockwise hysteresis in QS2i 
has also been reported in severe congestive heart 
failure patients after IV infusion (0.2 μg/kg/min for 
6 hours) or oral dose (2 mg), for which also the fact 
that levosimendan has inotropic and vasodilatory 
effects could contribute to development of 
hysteresis [48]. It is evident that in all cases the later 
effect is higher at 0 ng/mL than before the study 
commenced. These is exactly what would be 
predicted if you have a specific assay for the parent 
drug and have an active metabolite that is not 
detected or accounted for. More recent literature has 
demonstrated  that levosimendan has two active 
metabolites OR-1896 and OR-1855 that have mean 
elimination half-lives of 72.6 and 81.3 hours, 
respectively, compared to the elimination half-life 
of parent drug that ranges between 1.1 to 1.4 hours 
[324].   
 
Theoretical and Practical Considerations: 
Clockwise and Counter-clockwise Hysteresis and 
the Importance of Specific Measurement of 
Concentration 
Total (drug concentration + metabolites) together 
can be measured by a non-specific analytical assay 
method.
  







Figure 9. The concentration-effect loops for QS2i after single doses of 2 mg of levosimendan as an intravenous (n = 10) 
and three different oral formulations (n = 8) in healthy subjects. The levosimendan concentrations and corresponding QS2i 
values are plotted in the graph and the points are connected in time order. Reprinted by permission from Dustri-Verlag: 
International Journal of Clinical Pharmacology and Therapeutics, [49], copyright 1998. 
 
 
This would most often occur with the use of a 
radioimmunoassay, or by measuring radiolabelled 
drug in early pharmaceutical development. Using 
non-specific methods of analysis, drug 
concentration and concentration of metabolite 
would be measured simultaneously and could be 
plotted together versus effect. As presented in 
simulations by Gupta et al. [8] the potency of the 
parent compound and the generated agonistic 
metabolite (MA) were estimated using generated 
plasma concentration-time and plasma 
concentration-effect curves. Different derived 
equations were used to describe parent and MA PK, 
and  plasma concentration-effect profiles using PD 
models in which the effect was considered a linear 
function of parent and MA (equation 3) [8].  
 
MAMAPAR CPCPE   (3) 
 
where, PPAR is the pharmacological potency of the 
parent compound and PMA is the pharmacological 
potency of the metabolite. A competitive agonist 

















EE   (4) 
 
E vs. C plot is in actuality an E vs. C+CMA in these 
instances (Figure 10). When the parent compound 
and metabolite are equipotent no hysteresis was 
observed (PPAR/PMA ratio = 1 or EC50/EC50MA) 
(Figure 10a) Clockwise hysteresis was present 
when C > MA in potency (Figure 10 b) and 
counter-clockwise hysteresis was reflective of MA 
> C in potency (Figure 10c). Similar findings were 
demonstrated and applicable using Equation 3. 
Therefore, the potency of the metabolite relative to 
parent compound is the key to the hysteresis and its 
direction, and it needs to be considered that non-
specific analytical assays such as RIA or achiral 
analytical methods in PK-PD studies could cause 
interpretational problems but also warrants the need 
to identify all of the active metabolites or 
stereoisomeric forms.  






Figure 10. Plot of observed effect (E) vs. unbound plasma concentration (C + CMA) for parent compound and agonistic 
metabolite (MA). The pharmacodynamics of parent compound and MA are described by a linear model (Equation 3), and 
where, for MA pharmacokinetics, kmo = 0.05 and PPAR = 1: collapsed hysteresis with PMA = 1 (a), clockwise hysteresis with 
PMA = 0.33 (b) and counter-clockwise hysteresis with PMA = 3 (c). Reprinted by permission from Springer Science and 
Business Media: Pharmaceutical Research, [8], copyright 1993. 
 
 
What is apparent is that if using a non-specific 
method of analysis (Figure 11b), a direct linear 
relationship could be interpreted between 
concentration and effect (Figure 1a, Figure 11b), 
however employing a specific method of analysis 
(Figure 11a) demonstrates the existence of a 
counter-clockwise hysteresis loop. Likewise, a 
clockwise hysteresis loop could be incorrectly 
assigned to a situation where a counter-clockwise 
hysteresis is occurring (Figure 10a and Figure 11a). 
Finally, a larger counter-clockwise hysteresis may 
be evident (Figure 10c) than if a specific method of 
concentration analysis utilized (Figure 11a). 
 
Figure 11. (a) Plot of observed effect (E) vs. unbound 
plasma concentration for parent compound (C) showing 
counter-clockwise hysteresis. The pharmacodynamics of 
parent compound and agonist metabolite (MA) are 
described by a linear model, with PPAR = PMA = 1 and kmo 
= 0.05. (b) Plot of observed effect (E) vs. unbound 
plasma concentration (C + CMA) for parent compound 
and MA showing collapsed hysteresis, where the 
pharmacokinetic-pharmacodynamic model is as in a. 
Reprinted by permission from Springer Science and 
Business Media: Pharmaceutical Research, [8], copyright 
1993. 
 
Time-Dependent Protein Binding 
In a simulation study the time-dependent protein 
binding can occur as a consequence of a time 
dependent decrease in protein concentration in 
serum, by displacement of a metabolite. When 
pharmacological effect was plotted versus total drug 
concentration in serum counter-clockwise hysteresis 
was evident; however, when concentration of free 
drug in serum, which was correlated with 
pharmacological effect, was plotted no hysteresis 
was evident [9]. Time-dependent protein binding 
that can occur as a consequence of an increase in 
protein concentration in serum can lead to a 
decrease in free fraction of drug. When 
pharmacological effect was plotted versus total drug 
concentration in serum (i.e. free and bound drug) 
clockwise hysteresis was evident; however, when 
concentration of free drug in serum was correlated 
with pharmacological effect no hysteresis was 
evident [9]. Despite these theoretical simulations 
and modeling no examples of studies in the 
literature demonstrating this phenomenon are 
apparent to date. 
 
Racemic Drug and Chirality 
The utility of using non-stereoselective assay 
methodology for measuring concentration of a 





racemic drug can lead to interpretation errors in the 
concentration versus pharmacological effects 
correlation and the assignment of a hysteresis loop 
[10, 179]. Indeed as stated by Ariens 30 years ago 
[297] an analytical assay that does not measure the 
enantiomers of a racemic drug and attempts to 
relate total concentrations to effect without 
stereochemical knowledge is “highly sophisticated 
scientific nonsense”. However, many examples 
from studies in both Tables 2 and 3 continue to 
produce this achiral scientific gibberish. After oral 
administration when enantiomers differ 
substantially in total body clearance and when an 
active enantiomer has lower clearance, counter-
clockwise hysteresis was evident between plasma 
concentration of total drug and its pharmacological 
effect. The active enantiomer would constitute a 
greater proportion of the total concentration as time 
progresses. In addition, when the Vd of an active 
enantiomer is larger than the inactive enantiomer 
and a different half-life of the enantiomers ensues, 
the proportion of the active enantiomer in the total 
concentration would be higher over time. In the 
case of zero-order absorption, which could be 
possible when enantiomers are orally absorbed and 
transported via carriers, and when the Ka of the 
active enantiomer is less than that of the inactive 
enantiomer hysteresis was evident. The implications 
of chirality on pharmacodynamics modeling were 
also simulated when enantiomers acted as 
competitive agonists, partial agonists, competitive 
agonists, enantiomers may also have affinity and 
activity and intrinsic activity at separate receptors, 
separate transduction mechanisms or affinity and 
intrinsic activity at separate receptors but with a 
common transduction mechanism. When the more 
active enantiomer had higher clearance or a smaller 
volume of distribution plots of pharmacological 
effect versus non-stereospecific plasma 
concentration produced anti-clockwise hysteresis 
loops [179]. 
When a racemic drug’s active enantiomer has a 
higher total body clearance a clockwise hysteresis 
describes the relationship between total 
concentration and pharmacological effect as the 
active enantiomer would be a lower proportion of 
the total concentration over time. In addition, when 
the volume of distribution of active enantiomer is 
smaller than the inactive enantiomer and a different 
half-life of the enantiomers ensues, the proportion 
of the active enantiomer in the total concentration 
would be lower over time. In the case of zero-order 
absorption which could be possible when 
enantiomers are orally absorbed and transported via 
carriers and when the Ka of the active enantiomer is 
greater than that of the inactive enantiomer 
hysteresis was evident. 
Many studies identifying hysteresis using 
racemic drugs (i.e. Tables 2 and 3) and that have 
utilized non-stereospecific assays may therefore 
require further evaluation of their underlying 
mechanisms. The implications of chirality on 
pharmacodynamics modeling extended the 
importance of pharmacodynamics to the hysteresis 
relationship [179]. There are a variety of possible 
pharmacological interactions between enantiomers 
that were evaluated through the use of simulation of 
the pharmacological effect-time profile and 
ultimately clockwise hysteresis was also evident. 
Enantiomers may act as competitive agonists, 
partial agonists or competitive antagonists. 
Enantiomers may also have affinity and activity and 
intrinsic activity at separate receptors, separate 
transduction mechanisms or affinity and intrinsic 
activity at separate receptors but with a common 
transduction mechanism. In cases where the more 
active enantiomer had higher clearance and a 
smaller volume of distribution, plots of 
pharmacological effect versus non-stereospecific 
plasma concentration produced clockwise hysteresis 
loops. The plots outlined in Figures 10 and 11 are 
also applicable to achiral analysis of total 
enantiomers of a racemate [8,10, 179]. Depending 
on both the pharmacokinetic and pharmacodynamic 
behaviours of the enantiomers, the less active 
enantiomer may significantly affect the observed 
effect and therefore the reliability of any hysteresis 
loop obtained with the use of suspected achiral 
concentration data. All of the eight different 
clockwise hysteresis examples that use racemic 
drugs in Table 3 may be similar to Figure 10b but 
could in fact produce counter-clockwise hysteresis 
if stereospecificity was considered in the analysis. 
 
PHARMACOKINETIC-
PHARMACODYNAMIC (PK-PD) MODELING 
The general assumption is that drug in the surrogate 
biological matrix, such as plasma, and the drug at 
the biophase are at equilibrium [5]. However, this 
assumption may not be correct because the drug 
concentrations change as a result of the innate 
pharmacokinetics of the drug, and the 
pharmacodynamics could also change 
independently or in an opposite direction to the 





drug concentration. Various approaches for 
simultaneous PK-PD modeling have been explored 
[180], including compartmental models [181], 
system dynamics models [182], distributed log 
analysis [183], or numerical deconvolution [184]. 
All of these approaches have advantages and 
disadvantages due to the complexity of the inherited 
mathematical equations utilized.[185, 325-326]. 
 
 
Effect Compartment Model  
The most commonly used PK-PD model is the 
effect compartment model (Figure 12), which 
assumes that the active site compartment receives a 
negligible amount of drug and has a negligible 






Figure 12. Effect Compartment Model 
This approach has now been implemented in 
various modeling software with the so called non-
parametric or parametric link model [190].The use 
of an effect compartment model has been widely 
used to collapse the hysteresis loop, which is 
generally performed by linking it to the PK model 
as it was originally proposed by Segre [191] and by 
Galeassi et al. [192], and later elaborated and 
described by Holford and Sheiner [164] and by 
Sheiner et al. [3]. The effect compartment model 

















































where, Ce is the effect compartment concentration, 
KA is the absorption rate constant, K is the 
elimination rate constant, K21 is the transference rate 
constant from the peripheral to the central 
compartment, Vd/F is the volume of distribution 
corrected by the bioavailability of the oral dose D, α 
and β are the hybrid rate constants corresponding to 
the initial and terminal slope factors, respectively, 
and Ke0 is the constant of the disappearance of the 
effect [29, 164]. 
The main assumption necessary to make the 
hysteresis loop collapse is that the effect depends on 
the drug concentration in an effect compartment 
rather than in the systemic compartment. 
Furthermore, the effect is correlated to Ce by the 












   (6) 
 
where, E is the observed effect, Emax is the 
theoretical maximal effect that can be attained, Ce is 
the effect-compartment concentration, EC50 is the 
Ce value that produces an effect equivalent to 50% 
of the theoretical maximal effect and h is a 
parameter that determines the steepness of the 
curve. 
 





The fitting procedures then can be performed 
using a PK/PD modeling software. The effect 
compartment model has been applied to the 
observed counter-clockwise hysteresis between 
diclofenac blood concentrations and functional 
index (FI) recovery after oral diclofenac 
administration to male Wistar rats (Figure 13a) 
[29]. This hysteresis loop has been previously 
reported to be due to the formation of active 
metabolites; however, diclofenac metabolites do not 
exhibit anti-nociceptive activity [193, 194] and 
local administration of diclofenac causes an anti-
inflammatory effect [195]. Another proposed 
mechanism of action was a cascade of physiological 
events [196] because the anti-nociceptive effect of 
diclofenac is an indirect response from the 
inhibition of prostaglandin synthesis [197]; 
however, it has been reported that diclofenac has a 
rapid pharmacodynamic effect when administered 
locally [195] indicating that once it reaches the site 
of action it has a rapid pharmacological response 
without delay. Therefore, the lag in anti-nociceptive 
effect onset occurs because there is a slow 
equilibrium kinetics between blood concentration in 
the central and effect compartment [29]. The use of 
the effect compartment model results in the collapse 
of the hysteresis loop (Figure 13b), because the 
derived effect data exhibited good fit as a function 
of the estimated Ce [29]. 
 
Tolerance Model: Incorporation of the 
Hypothetical Non-Competitive Antagonist  
A tolerance model was developed by Prochet et al. 
[199] in which a hypothetical non-competitive 
antagonist is included to represent the factor driving 
tolerance (Figure 14), and this has been applied to 
diltiazem [86], clonidine [25], ephedrine [200], and 
morphine [41]. This model can describe tolerance 
based on competitive or non-competitive inhibition 
of response by down-regulation of receptors or by a 
metabolite [86].  
      
 
                             
 
Figure 13. (a) Relationship between the measured blood concentration of diclofenac and the observed anti-nociceptive 
effect expressed as FI recovery after oral administration of a 10 mg/kg sodium diclofenac dose to rats that were injected 
with uric acid in the right hind knee. (b) Relationship between the observed anti-nociceptive effect, measured as FI 
recovery, and calculated effect-compartment Diclofenac concentrations corresponding to PO administration of 0.56, 1, 1.8, 
3.2, 5.6 and 10 mg/kg of sodium diclofenac. Reprinted by permission from American Society for Pharmacology and 
Experimental Therapeutics: The Journal of pharmacology and experimental therapeutics, [29], copyright 1997. 
 






Figure 14. Tolerance Model 
 
 
where, E is the measured PR interval, E0 is the 
baseline PR interval, C is the drug plasma 
concentration, S is the slope of the linear 
relationship between effect and concentration in the 
absence of antagonist, Cant is the concentration of 
the hypothetical antagonist, and Cant50 is the 
concentration of hypothetical antagonist resulting in 
50% inhibition of effect. Hypothetical antagonist 
concentration units are those of steady-state drug 
concentrations [86]. 
In the case diltiazem after a single oral dose 
(120 mg) to healthy subjects, the same model was 
not only applied to parent drug but also to the 
metabolites N-desmethyldiltiazem and 
desacetyldiltiazem. The best fit of the various 
options tested was obtained with the incorporation 
of the hypothetical non-competitive antagonist 
rather than the use of any of the metabolite 
concentration (Figure 15) [86]. Panel B is the best 
fit. The 400- 800 min times demonstrate a lack of 
weighting. 
 
Indirect Physiological Response Turnover 
Model. 
As the pharmaceutical industry has diversified from 
small molecules into administration of proteins and 
peptides we have seen effects that are more 
discordant in time and production or degradation of 
a mediator that is often responsible for drug action. 
[321-330]  As the mechanism of action of many 
drugs involves protein synthesis, a drug may affect 
the net response measured by altering either then 
Kin or Kout that will evoke the response measured 
(Figure 16). Indirect models allow for a later Tmax 
with larger doses of drug. Of course partial 
inhibition or synergism can be adapted, circadian 
variation accounted and cascade models could be 
developed and transduction effects incorporated 
into these models. As many xenobiotics act 
indirectly through physiological and biochemical 
mediators and enzymes there is broad applicability 
of this approach. Jusko has pioneered the work in 
turnover model systems by pointing out that four 
main mechanisms are involved in stimulating or 
inhibiting production of the biosignal that is 
measured as the effect, or inhibiting or stimulating 
its removal [321-323].These models can be further 
extended by adding more transit compartments 
which are similar to steps in the transduction of the 




The appearance of hysteresis loops in PK-PD 
analysis indicates that the relationship between drug 
concentration and the effect being measured is not 
direct but has an inherent time delay and 
disequilibrium. As hysteresis depends on both 
pharmacokinetics and pharmacodynamics including 
all the innate factors affecting either of them this 
has a critical role in the appearance, direction, 
magnitude and collapse of a hysteresis loop. Some 
of these factors include the equilibrium / 
disequilibrium between sampled PK concentration 
and effect site concentration, rate of 
pharmacological receptor activation/deactivation, 
rate of signal transduction at the receptor level, 
presence of agonist or antagonist active metabolites, 
upregulation/downregulation of pharmacological 
response, rate of equilibration between arterial 
plasma concentrations (compartment delivering 
drug to effect site) and venous plasma 
concentrations (sampling compartment for 
concentration analysis), among others. 






Figure 15. Plots of PR interval versus time for subject 5 showing the results of pharmacodynamic fitting procedures. A, Fit 
to linear pharmacodynamic model assuming no tolerance. B, Fit to model of acute tolerance that incorporates the effect of a 
hypothetical antagonist. C, Fit to model of acute tolerance, assuming N-desmethyldiltiazem is an antagonist. D. Fit to 
model of acute tolerance, assuming desacetyldiltiazem is an antagonist. Reprinted by permission from Macmillan 
Publishers Ltd: Clinical pharmacology and therapeutics, [86], copyright 1989. 
 
 
Figure 16. Indirect Response Turnover Model 
 
 
In addition, the study design can play a major role 
since the availability of a specific analytical method 
plays a critical role in the ability to detect the 
pharmacologically relevant analyte (parent vs. 
metabolite, or racemate vs. enantiomer). Also, it is 
critical to understand the nature of the activity of a 
metabolite (namely agonist or antagonist) because 
generally an agonist metabolite would aid in the 
development of a counter-clockwise hysteresis, 
while an antagonist metabolite would do the same 
for clockwise hysteresis loops.  
It can be observed that hysteresis loops are 
present for a wide range of drugs and the 
mechanism of action (MOA) sometimes overlap 
between each other. In the case of clockwise 
hysteresis the most common MOA is tolerance, 





which is a constant concern in the therapeutic use of 
benzodiazepines, opioids and CNS drugs. However, 
tolerance has also been reported for loop diuretics 
and nitrates. Feedback mechanisms can also play a 
critical role in hysteresis because they control 
various physiological processes and it has been 
reported that they can also decrease the 
pharmacological effect for the same drug 
concentrations, which could cause inhibition and/or 
depletion at the terminal/receptor level [93, 201, 
202]. Another factor to consider is drug and effect 
location and the protective barriers surrounding the 
active site such as the brain. As the brain possesses 
a protective blood-brain barrier (BBB) it would be 
expected that a delay in reaching the site of action 
would occur. Another factor that may be neglected 
in PK-PD interpretation is the potential differences 
in arteriovenous concentrations of a drug, because 
arterial blood delivers the drug to the effect site and 
venous blood is typically the sampled matrix. This 
for instance has been observed for thiopental in 
which concentrations were higher in the arterial 
samples during infusion but became comparable to 
venous samples after the infusion, and at the time of 
adding the pharmacodynamics component (EEG 
frequency reduction by spectral edge analysis), it 
was observed that the hysteresis loop was evident 
for arterial but not for venous blood [165].   
The current ability to measure receptor binding 
using positron emission tomography (PET) or an 
equivalent technology can help us understand better 
the rate at which drugs bind to the receptor (kon) and 
the rate at which it dissociates from a receptor (koff) 
to determine the kinetics of drugs such as anti-
psychotics, in which the kon values show low 
variability, but the koff can vary within a 1000-fold 
range [112]. This interplay is critical  because with 
the help of PET the dopamine receptor occupancy 
after single oral administration of aripiprazole was 
evaluated. It was observed that high receptor 
occupancy was present after the administration 
(lower arm of hysteresis) but low receptor 
occupancy was observed at later time points post 
drug administration (upper arm of hysteresis) [12]. 
The relevance of using different pharmaceutical 
formulations and routes of administrations has been 
presented to illustrate the need to be considered in 
order to achieve the desired therapeutic profile. For 
instance, bumetanide as a tablet exhibited counter-
clockwise hysteresis because a time lag between 
plasma concentration and diuretic effect is evident 
since the drug acts directly in the renal tubule or 
because of variations in absorption rate from the GI 
tract. However, in the case of the retarded capsules 
a clockwise hysteresis was present because the 
maximum urine flow rate was achieved before the 
plasma Cmax or before the maximum of urinary 
excretion [20]. Thus, it can be clearly observed that 
the pharmaceutical formulation may change the 
pharmacodynamics of a drug. However, the change 
from one formulation to another does not follow a 
constant pattern in the direction of occurrence of a 
hysteresis loop as this is dependent on the drug 
itself and the actual effect site. Other drug delivery 
formulation approaches have centered on the 
modification of the lipophilicity of a drug and 
having a closer delivery to the site of action in order 
to try to circumvent biological barriers. For 
instance, morphine and fentanyl were formulated 
into a pressurized olfactory delivery (POD) device. 
Clockwise hysteresis was observed after POD 
administration of both morphine and fentanyl, but 
counter-clockwise hysteresis was observed after 
nasal drops and IP administration of morphine, 
while no clear hysteresis after nasal drops and IP 
administration of fentanyl [57]. These observed 
differences could be attributed to significant 
differences in hydrophobicity and ability to 
penetrate the BBB, which not only affected the 
systemic plasma concentrations but also the 
delivery to the nasal olfactory epithelium.  
With the relevance that hysteresis loops have, 
various modeling approached have been proposed 
to collapse hysteresis and allow for adequate PK 
and PD estimates, and the most commonly used 
model remains the effect compartment model, 
which assumes that the active site compartment 
receives a negligible amount of drug and has 
negligible volume [4, 164, 186-189]. However, 
variation of this model such as the tolerance model 
has also been implemented [102] where a tolerance 
(use of a linear PD model) and pseudo-tolerance 
(use of an effect compartment model) PK-PD model 
were evaluated for different drugs [104, 105, 203]. 
Also as proposed by Gupta et al. [8], the potency of 
the metabolite relative to parent compound is the 
key to the hysteresis and its direction, and it needs 
to be considered that non-specific analytical assays 
such as RIA or achiral analytical methods in PK-PD 
studies could cause interpretational problems but 
also warrants the need to identify all of the active 
metabolites and enantiomers.  
Ultimately it can be seen that the presence of a 
hysteresis loop provides guidance on how to model 





pharmacokinetic-pharmacodynamic relationship of 
a particular drug, it allows the pharmaceutical 
scientist to design studies more appropriately when 
arteriovenous drug versus venous concentration 
differences are large and to provide a more rational 
basis for dosage individualization. A very clear 
example is the case of piritramide, for which it is 
recommended that it should be initially 
administered as an intravenous bolus of at least 5 




The linking of pharmacokinetics and 
pharmacodynamics is taking on greater relevance 
because of the necessity to understand the 
concentration-time profiles of drugs and the need 
for the ability to determine dosing regimens that 
will achieve the necessary concentrations for 
optimal efficacy. These complex relationships have 
allowed us to be able to detect hysteresis loops and 
to begin to understand the various mechanisms of 
action, metabolic and rate limiting steps that cause 
them. It can be observed that there are various 
modeling alternatives to collapsing hysteresis loops 
when determining PK and PD estimates. Special 
attention needs to be placed on the study design 
with the various caveats that could arise from the 
selection of PD estimates as well as the selection of 
formulation and route of administration. Inter-
disciplinary approaches are warranted to aid in the 
further understanding of hysteresis loops to help us 
develop drugs with a clearer understanding of their 
complicated pharmacokinetic-pharmacodynamic 
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Urine flow 
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dissociation from the 
















1 mg/kg single sub cut 
injection 
Slow permeation over 





Fantofarone Calcium antagonist 
6 humans 
(healthy) 















 18 humans (4 
healthy and 14 
with impared 
renal function) 
10 mg felodipine orally 
as steady state 
Slow equilibrium 

















Fenretinide Synthetic retinoid  
50 children with 
neuroblastoma 
100-4000 mg/m2 po 
daily for 28 days 






Fenretinide (µM) [35] 
(+/-) Fexofenadine H1-antagonist 
6 humans 
(healthy) 
60 mg po tablet 
Equilibration delay 
between the plasma 
















changes by the 
sustained release 
formulation is not only 
due to systemic 
availability of the 
NSAID since it may be 
also resulted from 
continuous exposure of 








Furosemide Loop diuretic 
26 humans 
(healthy) 
60 mg tablet po Delay of effect 
Diuresis 
(mL/min) 
Furosemide excretion rate 
(µg/min) 
[38]* 
Furosemide Loop diuretic 
4 humans 
(healthy) 
40 mg IR tablet po 
Inhibition of the 
reabsorption of sodium 
and chloride at Loop of 
Henle was delayed due 
to fast absorption 




Excretion rate of 
furosemide (mg/h) 
[39]* 






40 mg tab po single 
dose 
Delay in drug action/ 
delay in equilibrium 
Furosemide 
excretion rate 




Furosemide Loop diuretic 
8 humans 
(healthy) 
10 mg iv infusion over 
10 minutes 
Delay between 




























10 Units regular insulin 
given subcutaneously 
or 25 Units NPH given 
subcutaneously as 
single dose  



















150 or 300 mg tablet 
po single dose 
Vasodilatory effect of 














2 mg/kg or 5 mg/kg po 
dose (2 treatments 3 
weeks apart) 
Time needed for the 
drug distribution from 
the central 
compartment to AT1 
receptors 
Inhibitory 










2 mg iv over 15 min, 
5 mg sublingual tablet 
Changes in blood 
pressure response lag 



















1 mg iv infusion 
5 mg po solution 
5 mg tablet 









(+/-) Itraconazole Antifungal agent Rats 
5 & 40 mg/kg 5 min 
infusion 
Factors other than 
itraconazole determine 
the time course for the 












10 mg po tablet 
Equilibration delay 
between the plasma 
concentration and effect 
site 










0.2 µg/kg/min 6 hr 
continuous infusion or 
2 mg single po dose 
Delay of drug 
distribution to its 












Levosimendan (ng/mL) [48] 
Levosimendan Calcium sensitizer  
10 humans 
(healthy) 
2 mg iv, tablet, 
capsule, SR tablet 
(single doses) 
 
Takes time for the drug 
to distribute from 
plasma to its cardiac 
site of action 
 
Δ QS2i (ms) 
Plasma concentrations of 
levosimendan 
[49] 







Anesthetic 5 sheep 
50 mg, 75 mg and 
100mg iv bolus 
Lack of pseudo 
equilibrium between 
the drug concentrations 
in the blood and at the 
receptor sites 
responsible for drug 







concentrations (µg/mL) in 
arterial blood and 






1.5 mg/kg ip D-
amphetamine base 













in the striatum (% of 
baseline) 
[28]* 
(+/-) Lorazepam Benzodiazepine 
6 humans 
(healthy) 
0.057 mg/kg solution 
single oral dose 
The site of action of 
lorazepam is kinetically 
distinguishable from 
the plasma 
compartment and there 
is a distinct time lag 
between changes in 
plasma concentration 










(+/-) Lorazepam Benzodiazepine 
9 humans 
(healthy) 
2 mg bolus iv loading 
dose followed by a 2 
µg/kg/hr infusion for 4 
hrs 
Delay in equilibration 
of lorazepam between 
plasma and the site of 
pharmacodynamics 





























(+/-) Meperidine Opioid analgesic Sheep 









myocardium and coronary 














500 mg po 
Time delay between the 
change in plasma 
concentration and the 
drug effects 

















concentration in the 
plasma and drug 










0.1 mg/kg constant rate 











0.03 mg/kg and 0.07 
mg/kg iv infusion (four 
separate occasions) 














7.5, 15, and 25 mg  iv 
infusion at 5 mg/min 
Disequilibrium 































Morphine (ng/ml) [57]* 
(+/-) 
Morphine 
Opioid analgesic Rats 
14.0 mmol/kg 
morphine 
Delay of polar 













Opioid analgesic Rats 













Concentration of blood 
morphine (µg/L), 
concentration of CSF 










Morphine Opioid analgesic Rats 
10 minute i.v. infusion 













6 mg/kg po (single 
dose) 
Slow transport of 
naproxen from 










10, 20, 40 µg/min iv 
infusions 
End product inhibition 
or saturable binding of 




Infusion rate (µg/min) [61] 
Nitroglycerin Vasodilator 4 dogs 















25 U single 
subcutaneous dose 
















2 or 4 µg/kg/min by 













0.27 mg/kg single sub 
cut injection 
Slow permeation over 





(+/-) Penbutolol Beta-blocker 
7 humans 
(healthy) 


































7.5 mg po 









Pimobendan in plasma 
(ng/mL) 
[65] 





Pinacidil Vasodilator  
12 humans 
(healthy) 
25 mg tablet or capsule 
po once daily for 1 
week 





















Propofol General anesthetic Sheep 
100 mg iv infusion 
over 2 min 
Disequilibrium due to 
organ drug uptake 















(+/-) Propranolol Beta-blocker 6 humans 
3 x 20 mg PL po tablet 
or 60 mg LA po tablet 
Two distinct beta-
adrenoceptor binding 
sites on the surface 








(+/-) Quinine Antimalarial 
6 humans 
(healthy) 
15 mg/kg po dose and 
15 mg/kg iv infusion 



























Oral administration of 
8.5, 17, and 34 mg/kg;  
3.13, 6.25, 12.5, 25, 
and 50 mg/kg; and 
3.13, 6.25, 12.5, 25, 
and 50 mg/kg 














Single 50 mg and 25 
mg iv doses  





Regular insulin Peptide hormone 
10 humans 
(healthy) 
10 U single 
subcutaneous dose 









Remifentanil Opioid analgesic 
10 humans 
(healthy) 
3 µg/kg/min for 10 
minutes 
Equilibrium delay 
between arterial opioid 
concentration and 
concentration at the site 

















1 mg po (single dose) 
Drug moves from the 
plasma to the effect 
compartment after time 
delay 
EEG effect 







20, 40 mg/kg/h iv over 
90 min 
Delayed distribution in 
the effect site, 
potassium channels on 
ventricular myocytes 
Change in QT 
interval 
(msec) 







2.2 mg/kg single sub 
cut injection 
Slow permeation over 





Sevoflurane General anesthetic 
21 Humans 
(healthy) 
Inhalation initially at 
1% then increased by 
1% to a max of 8%. 
Then decrease to 1% 
Delay of drug 













DOPA 100mg po 
Takes time for L-
DOPA to distribute to 
the central nervous 
system 
Taps per 60 
seconds 






Prograf single injection 
0.1 and 5mg/mL 
Delay in distribution of 









5 guinea pigs 
0.01 or 0.1 mg/hr/kg iv 
infusion 
The delay in 
distribution from blood 













20, 40, 80mg po 
Delay and longer 
persistence of effect 
than expected, slow 
dissociation from the 
receptor 
Inhibition (%) 








4 µg /kg/min for a 
maximum of 30 






















Distribution of the 
molecules between the 















4 sheep 750 mg iv over 2 min 
Presence of effect 
compartment 
Maximum 







of arterial (µg/mL) and 





6 dogs 4 mg/kg sC 













1 mg solution po 
(single dose) 
The site of action of 




contains a distinct time 
lag between changes in 
the plasma 
concentration and 
changes in CNS effect 
Subcritical 
tracking, body 
sway and digit 
symbol 
substitution 





250µg po capsule 
500µg po capsule 
250µg po solution 
Delay in equilibrium 
between plasma 
concentrations and 
concentrations at the 















Single dose i.v. 
infusion (0.15 – 0.22 
mg/kg) 
Time lag between 
plasma verapamil 
concentrations and 
maximal drug effect on 
AV conduction 

























+/- Indicates Racemic Drug with Enantiomers 
* Indicates Drug listed in both Table 2 and 3 

































Venous blood samples 








2 mg po (two single 






















75 mg po controlled 























disease with end 
of dose 
fluctuations) 















pellets 16mg/kg po 
single dose 
 
Tolerance induced by 
desensitization or 





















5 mg capsules  bid po 
or 
10 mg capsules once 
daily po 
Compartment effect or 
an indirect response 






Bumetanide Loop Diuretic 
3 humans 
(healthy) 
1mg SR capsules po Tolerance 
Urine flow 
rate (ml/hr) 
Plasma concentration of 
bumetanide (ng/ml), 
urinary excretion rate of 
bumetanide (µg/h) 
[20]* 
Bumetanide Loop Diuretic 
3 humans 
(healthy) 
1 mg IR tablet po Tolerance 
Urine flow 
rate (ml/h) 







Smoked doses (10, 20, 
and 40 mg) 
Tolerance (acute) 
Mean change 







Cocaine Drug of abuse 
9 humans 
(healthy) 
Smoked dose (12.5, 
25, and 50 mg) and i.v. 
doses (8, 16, 32 mg) 
Rapid distribution of 
drug to the brain 
Mean change 






high or drug 
liking 







30 or 60 mg/kg iv 
infused  over 20 min 
or 30, 60, or 120 








































in the striatum (% of 
baseline) 
[28]* 

















Diazepam plasma level x 










120 mg po single dose 
















180 mg SR capsule 
with wax matrix 















0.3, 1, 3 mg/kg 
po (single dose) 
Time lag between 
arrival of distigmine at 
the site and the onset of 
its inhibitory effect. 
AChE activity 
(%) 
Plasma Concentration of 
distigmine (ng/ml) 
[88] 









Fentanyl (ng/ml) [57]* 
Furosemide Loop diuretic 
26 humans 
(healthy) 






Furosemide excretion rate 
(µg/min) 
[38]* 
Furosemide Loop diuretic 
8 humans 
(healthy) 
10 mg iv infusion over 







Furosemide excretion rate 
(µg/min) 
[41]* 
Furosemide Loop diuretic 
4 humans 
(healthy) 
40 mg SR tablet po Tolerance 
Diuretic rate 
(ml/h) 
Excretion rate of 
furosemide (mg/h) 
[39]* 




















Furosemide excretion rate 
(µg/hr) 
[40]* 





Furosemide Loop diuretic 
8 humans 
(healthy) 
40 mg iv after 
breakfast 




















Single IV bolus 
injections of 
0.03 or 0.06 mg/kg 
GOT 












2000 IU continuous 
infusion over 40 min 
Tolerance 
- may be caused by 












Anti-IIa activity (U ml-1), 








24 humans (mild 
to moderate 
hypertension) 
300 mg po once daily 













Opioid analgesic Sheep 
100 mg iv dose over 1 
second 
Tolerance 




myocardium and coronary 












ratio to basal 
Methylphenidate 

































Morphine (ng/ml) [57]* 







Opioid analgesic 280 rats 




Tolerance due to drug 
induced desensitization 
of receptors or counter 
regulatory substances 




Concentration of blood 
morphine (µg/L), and 
concentration of CSF 





















(+/-) Nicotine Stimulant 
8 humans 
(healthy) 
2.5 µg/kg/min iv for 

























7 µg kg-1 min-1 up to 
maximum 0.2 mg/kg 
Equilibration delay of 
piritramide between 
plasma concentration 









Piritramide  concentration 
measured (µg/L) 






18 rats 150 mg/kg·h 
Delay of equilibrium of 







Propofol General Anesthetic Rats 
30 mg/kg in 5 min iv 
bolus infusion and 150 
mg/kg iv continuous 
infusion (5 hrs) 
-both doses tested as 
1% in Intralipid® 
10%, 1% in 






































concentration and the 
effect site occurs more 
rapidly than equilibrium 















0.5 mg iv infusion 
over 15 min. 















30 mg/kg, 60 mg/kg or 
100 mg/kg iv infusions 
over 30 min 
1) Inhibition of PDH-
kinase could be 
reversible at low 
concentrations of DCA, 
becoming 
irreversible at high 
concentration 
2) PDH-kinase binding 
of DCA may be more 
rapid than dissociation 
3) There may be 
Substantial redundancy 
in the amounts of DCA 
bound compared 
with that needed for 
maximal effect, or 4) A 
combination 











Active metabolite of 
spirapril (ACEI) 
























30 mg capsule po (two 
single doses) 
Tolerance- discrepancy 
between plasma t1/2 


































Blood sample from 
forearm vein zopiclone 
(ng/ml) 
[102] 
+/- Indicates Racemic Drug with Enantiomers * Indicates Drug listed in both Table 2 and 3
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